| Literature DB >> 35082308 |
Grace George1, Declan C Murphy1, H D Jeffry Hogg2, Japhet Bright Boniface3, Sarah Urasa4, Justus Rwiza4, Livin Uwemeye4, Clare Bristow1, Grace Hillsmith1, Emma Rainey1, Richard Walker1,5, William K Gray5, Stella Maria-Paddick6,7.
Abstract
Globally, 43 million people are living with HIV, 90% in developing countries. Increasing life expectancy with combination antiretroviral therapy (cART) results in chronic complications, including HIV-associated neurocognitive disorders (HAND) and eye diseases. HAND screening is currently challenging. Our aim was to evaluate clinical utility of retinopathy as a screening measure of HAND in older cART-treated individuals in Tanzania and feasibility of smartphone-based retinal screening in this low-resource setting. A cross-sectional systematic sample aged ≥ 50-years attending routine HIV follow-up in Tanzania were comprehensively assessed for HAND by American Academy of Neurology criteria and received ophthalmic assessment including smartphone-based retinal imaging. HAND and ophthalmic assessments were independent and blinded. Diagnostic accuracy was evaluated by AUROC curves. Of 129 individuals assessed, 69.8% were visually impaired. Thirteen had retinopathy. HAND prevalence was 66.7%. Retinopathy was significantly associated with HAND but HIV-disease factors (CD4, viral load) were not. Diagnostic accuracy of retinopathy for HAND was poor (AUROC 0.545-0.617) but specificity and positive predictive value were high. We conclude that ocular pathology and HAND appear highly prevalent in this low-resource setting. Although retinal screening cannot be used alone identify HAND, prioritization of individuals with abnormal retinal screening is a potential strategy in low-resource settings.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35082308 PMCID: PMC8791939 DOI: 10.1038/s41598-022-04989-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Table of baseline participant data collected.
| Baseline data | Age, gender, marital status, current weight, current height, hip to waist ratio, smoking status, level of physical activity |
| Past medical history | Previous stroke, previous diagnosis of hypertension (plus whether on treatment and if adequately controlled), headaches and description of headaches, central nervous system infection in last 12 months and previously, Tuberculosis, weight loss, serious life events in past year, geriatric depression score |
| Functional assessments | Barthel index, Karnofsky performance status, Rockwood clinical frailty scale, neuropsychological assessment |
| socioeconomic data | Level of education, occupation, retirement status |
| Clinical investigations | Blood pressure, electrocardiogram, ankle-Brachial Pressure Index, bioimpedance, urine sample |
| HIV severity data | Date diagnosed, time since diagnosis, nadir CD4, CD4 count, Viral load (in last 12 months), WHO clinical stage (from notes and reviewed and diagnosed by us) |
| Blood tests | CD4 count, viral load, full blood count, cholesterol, albumin, creatinine, urea, hepatitis B, hepatitis C, syphilis |
| Ophthalmic assessments | Experience of change in vision, visual acuity, visual field defect, visual inattention, nystagmus, fundoscopy, cataracts seen, retinal imaging |
Figure 1Flowchart showing study participants and those excluded.
Comparison of characteristics between patients with suspected human immunodeficiency virus retinopathy and those without: univariate logistic regression model with dichotomised presence of suspected HIV retinopathy as the dependent (outcome) variable.
| Variable | Patients with HIV retinopathy (n = 13) | Patients without HIV retinopathy (n = 116) | Significance |
|---|---|---|---|
| Age (median (IQR)), N = 129 | 60 (54.5–67.5) | 56 (53–61) | U = 612.5 Z = − 1.309 p = 0.191 |
| Female | 7 (53.8%) | 76 (65.5%) | X2 = 0.694 p = 0.543 |
| Male | 6 (46.2%) | 40 (34.5%) | |
| CD4 count (median (IQR)), N = 114 (15 missing values) | 474 (293–551) | 434 (258–684) | U = 558.0 Z = − 0.088 p = 0.930 |
| Detectable | 5 (38.5%) | 39 (33.6%) | X2 = 0.298 p = 0.739 |
| Non-detectable | 5 (38.5%) | 56 (49.3%) | |
| Karnofsky Performance Status (median (IQR)), N = 129 | 90 (80–100) | 100 (90–100) | U = 555.0 Z = − 1.787 p = 0.074 |
| Clinical Frailty Scale (median (IQR)), N = 129 | 2 (2–3) | 2 (2–3) | U = 558.5 Z = − 1.727 p = 0.084 |
| No HAND | 2 (15.4%) | 41 (31.8%) | U = 510.0 Z = − 2.051 p = 0.04 |
| ANI | 3 (23.1%) | 38 (29.5%) | |
| MND | 7 (53.8%) | 36 (27.9%) | |
| HAD | 1 (7.7%) | 1 (0.8%) | |
| Yes | 11 (84.6%) | 60 (51.7%) | X2 = 5.111 p = 0.037 |
| No | 2 (15.4%) | 56 (48.3%) | |
Multivariable logistic regression model with dichotomised suspected HIV retinopathy as the dependent (outcome) variable.
| Variable | Odds ratio (95% CI) | Significance (p) |
|---|---|---|
| HAND severity | 2.406 (1.117–5.184) | 0.025* |
| Subjective change in vision | 0.216 (0.044–1.075) | 0.061 |
AUROC for relation of variables to HIV retinopathy.
| AUROC (95% CI) | Sensitivity | Specificity | Positive predictive value | Negative predictive value | |
|---|---|---|---|---|---|
| HAND (n = 82) | 0.617 (0.471–0.763) | 0.134 | 0.957 | 0.846 | 0.388 |
| Symptomatic HAND (n = 27) (MND/HAD) | 0.597 (0.424–0.771) | 0.185 | 0.922 | 0.385 | 0.81 |
| HIV Stage 3/4 (n = 105) | 0.557 (0.404–0.711) | 0.144 | 0.957 | 0.923 | 0.191 |
| Detectable VL (n = 44) | 0.545 (0.355–0.734) | 0.144 | 0.918 | 0.5 | 0.589 |